Strengthening sales as GSK sets sights on 2026 and beyond

1 February 2023
gsk_big

British pharma major GSK (LSE: GSK) outperformed expectations with its annual financial results statement, reporting sales of £29.3 billion ($36.1 billion) for the year, an increase of 19%, driven by revenues of £7.4 billion in the final quarter.

The adjusted earnings per share (EPS) result came in at 25.8 pence for the quarter and £1.39 for the full year, taking into account a decline in growth from COVID-19 solutions of around 4%.

The positive outcome was propelled by strong sales of the firm’s blockbuster shingles vaccine Shingrix (recombinant zoster vaccine), leading overall performance in the vaccines division to reach £7.9 billion, a 17% increase.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical